Ceesay Abraham — SEC insider filings

SEC reporting owner CIK 1722140. 31 insider filings on record with FilingPulse; latest filed 2026-10-23.

Transaction summary — filings shown

Covers all 31 filings on record, filed 2021-06-03 to 2026-10-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Rapport Therapeutics, Inc. (RAPP)Chief Executive Officer, Director18—44 legs · 237,212 sh · $8,285,7383
Cerevel Therapeutics Holdings, Inc. (CERE)President7—6 legs · 96,056 sh · $3,255,04814
Pacira BioSciences, Inc. (PCRX)Director4—1 leg · 2,354 sh · $64,0055
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)Director2——3

Insider filings — Ceesay Abraham

FiledFormIssuerReported transactionsSource
2026-10-234Rapport Therapeutics, Inc. (RAPP)Sale (S): 2,210 @ $29.16EDGAR
2026-10-084Rapport Therapeutics, Inc. (RAPP)Sale (S): 3,375 @ $32.03 · Sale (S): 1,147 @ $30.66EDGAR
2026-09-244Rapport Therapeutics, Inc. (RAPP)Sale (S): 1,952 @ $39.05 · Sale (S): 215 @ $39.86 · Sale (S): 43 @ $41.05EDGAR
2026-09-094Rapport Therapeutics, Inc. (RAPP)Sale (S): 7,141 @ $45.55 · Sale (S): 1,069 @ $46.01EDGAR
2026-08-264Rapport Therapeutics, Inc. (RAPP)Sale (S): 18,921 @ $49.57EDGAR
2026-08-124Rapport Therapeutics, Inc. (RAPP)Sale (S): 14,171 @ $45.97 · Sale (S): 8,370 @ $46.75 · Sale (S): 3,664 @ $46.90 · Sale (S): 19,500 @ $48.04 · Sale (S): 5,794 @ $48.62EDGAR
2026-07-294Rapport Therapeutics, Inc. (RAPP)Sale (S): 2,203 @ $42.11 · Sale (S): 7 @ $42.73EDGAR
2026-07-154Rapport Therapeutics, Inc. (RAPP)Sale (S): 5,481 @ $39.72 · Sale (S): 2,729 @ $40.57EDGAR
2026-07-014Rapport Therapeutics, Inc. (RAPP)Sale (S): 7,344 @ $39.77 · Sale (S): 876 @ $40.34EDGAR
2026-05-114CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)Grant/award (A): 1,438 @ $177.62EDGAR
2026-02-194Rapport Therapeutics, Inc. (RAPP)Sale (S): 3,552 @ $29.05 · Sale (S): 2,281 @ $29.80 · Sale (S): 2,983 @ $29.04 · Sale (S): 2,100 @ $29.80EDGAR
2026-02-044Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 428,000 (derivative) @ $0EDGAR
2026-01-224Rapport Therapeutics, Inc. (RAPP)Sale (S): 5,833 @ $26.12 · Sale (S): 5,083 @ $26.11EDGAR
2025-12-184Rapport Therapeutics, Inc. (RAPP)Sale (S): 2,441 @ $28.84 · Sale (S): 2,792 @ $30.04 · Sale (S): 600 @ $31.04 · Sale (S): 2,147 @ $28.84 · Sale (S): 2,421 @ $30.04 · Sale (S): 515 @ $31.04EDGAR
2025-11-184Rapport Therapeutics, Inc. (RAPP)Sale (S): 2,777 @ $24.92 · Sale (S): 3,056 @ $25.43 · Sale (S): 2,242 @ $24.91 · Sale (S): 2,841 @ $25.44EDGAR
2025-10-164Rapport Therapeutics, Inc. (RAPP)Sale (S): 4,647 @ $25.72 · Sale (S): 1,186 @ $26.14 · Sale (S): 4,328 @ $25.75 · Sale (S): 755 @ $26.17EDGAR
2025-09-194Rapport Therapeutics, Inc. (RAPP)Sale (S): 39,435 @ $26.30 · Sale (S): 1,400 @ $26.87 · Sale (S): 34,885 @ $26.30 · Sale (S): 700 @ $27.04EDGAR
2025-09-084Pacira BioSciences, Inc. (PCRX)Sale (S): 2,354 @ $27.19EDGAR
2025-06-134Pacira BioSciences, Inc. (PCRX)Grant/award (A): 6,163 @ $0 · Grant/award (A): 11,279 (derivative) @ $0EDGAR
2025-06-044CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)Grant/award (A): 946 @ $135.04 · Grant/award (A): 2,082 (derivative) @ $135.04EDGAR
2025-02-044Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 428,000 (derivative) @ $0EDGAR
2024-06-134Pacira BioSciences, Inc. (PCRX)Grant/award (A): 5,230 @ $0 · Grant/award (A): 12,179 (derivative) @ $0EDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 530,647 (derivative) @ $0EDGAR
2023-10-114Pacira BioSciences, Inc. (PCRX)Grant/award (A): 30,967 (derivative) @ $0EDGAR
2023-02-084Cerevel Therapeutics Holdings, Inc. (CERE)Grant/award (A): 114,445 (derivative) @ $0 · Grant/award (A): 29,083 (derivative) @ $0EDGAR
2022-09-124Cerevel Therapeutics Holdings, Inc. (CERE)Option exercise (M): 19,210 @ $13.17 · Sale (S): 19,210 @ $32.50 · Option exercise (M): 19,210 (derivative) @ $0EDGAR
2022-08-244Cerevel Therapeutics Holdings, Inc. (CERE)Option exercise (M): 9,605 @ $13.17 · Sale (S): 9,605 @ $32.50 · Option exercise (M): 9,605 (derivative) @ $0EDGAR
2022-08-174Cerevel Therapeutics Holdings, Inc. (CERE)Option exercise (M): 9,606 @ $13.17 · Sale (S): 9,606 @ $34.12 · Option exercise (M): 9,606 (derivative) @ $0EDGAR
2022-08-094Cerevel Therapeutics Holdings, Inc. (CERE)Option exercise (M): 38,424 @ $13.17 · Sale (S): 38,424 @ $32.50 · Option exercise (M): 19,211 @ $13.17 · Sale (S): 9,606 @ $37.75 · Sale (S): 9,605 @ $39.50 · Option exercise (M): 38,424 (derivative) @ $0 · +1 moreEDGAR
2022-02-114Cerevel Therapeutics Holdings, Inc. (CERE)Grant/award (A): 120,310 (derivative) @ $0EDGAR
2021-06-034Cerevel Therapeutics Holdings, Inc. (CERE)Grant/award (A): 461,065 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-06-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1722140 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs